Bioelectronics Corp (BIEL)

[Rocker424]

Paul's update email definitely sounds positive. Sounds like BIEL did a good job explaining the technology and how it works, and why the FDA might have overlooked the classification at first. It seems like the FDA brought a lot of people in to the meeing (20+) from all different areas.

What is also encouraging is that another meeting is scheduled in July. FDA isn't putting BIEL on the backburner - they have set up another meeting one month away. That is a good sign as well.

Sounds like FDA is willing to reconsider the Allay application at this point. If Allay is approved, than Actipatch would seem to be easy (already have a predicate device in place). The only reason RecoveryRx needs a separate meeting is because it's a different product with a higher power level that can only be prescibed by physicians.